{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"VolitionRx Announces Collaboration with Sysmex - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"ABsThY04hv\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/volitionrx-announces-collaboration-with-sysmex\/\">VolitionRx Announces Collaboration with Sysmex<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/volitionrx-announces-collaboration-with-sysmex\/embed\/#?secret=ABsThY04hv\" width=\"600\" height=\"338\" title=\"&#8220;VolitionRx Announces Collaboration with Sysmex&#8221; &#8212; Market Newsdesk\" data-secret=\"ABsThY04hv\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"PR Newswire HENDERSON, Nev., June 17, 2026 \/PRNewswire\/ &#8212; VolitionRx Limited (NYSE AMERICAN: VNRX) (&#8220;Volition&#8221;), a multi-national epigenetics company, announces a collaboration with Sysmex (TYO: 6869), a leader in global in vitro diagnostics, to optimize Volition&#8217;s Nu.Q\u00ae NETs H3.1 assay on the Sysmex platform. Gael Forterre, Chief Commercial Officer, Volition commented: &#8220;We are proud to have entered into this agreement with Sysmex, as we implement our strategy to out license our proprietary Nu.Q\u00ae NETs test to large companies with a worldwide presence, to leverage their knowledge of specific diseases, product development, regulatory experience and their installed base of proprietary analyzers. Sysmex is a global leader in the field of in vitro\u00a0diagnostics for hemostasis and thrombosis, among other diseases, where Neutrophil &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=LN86013&amp;sd=2026-06-17"}